Tag: LimFlow
Personalised postoperative anticoagulation needed to curb lower limb amputations
“We’re going to see more and more amputations if we don’t figure out the right post procedure thromboprophylaxis regime ASAP,” Anahita Dua (Boston, USA)...
Deep vein arterialisation: “A real advance” for treatment of ‘no-option’ CLTI
Daniel Clair (Vanderbilt University Medical Center, Nashville, USA) speaks to Vascular News at this year’s VEITHsymposium (14–18 November, New York, USA) on deep vein...
Inari Medical completes LimFlow acquisition for CLTI treatment
Inari Medical has announced that it has completed its acquisition of chronic limb-threatening ischaemia (CLTI) treatment maker LimFlow.
The Irvine, California–based company earlier this month...
PROMISE II 12-month data show durable outcomes with the LimFlow system...
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the...
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical.
A press release details that, under the terms...
US FDA approves LimFlow system for treatment of CLTI
The US Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries...
Results from PROMISE II pivotal trial suggest “transformational value” of deep...
Results from the PROMISE II pivotal trial investigating transcatheter arterialisation of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischaemia...
Vascular News’ top 10 most popular stories of November 2022
November's top 10 includes the first results from BEST-CLI, as well as new data presented at this year's Vascular Interventional Advances (VIVA; 31 October–3...
Vascular News’ top 10 most popular stories of March 2022
A review of intraoperative adverse events in patients treated with fenestrated and branched endovascular aneurysm repair, meta-analysis findings on peripheral arterial disease symptoms in...
LimFlow raises US$40 million in Series D financing
LimFlow recently announced it has closed a US$40 million (€36 million) oversubscribed Series D financing round.
A press release reports that new investors Longitude...
PROMISE II US pivotal trial of device designed for “no-option” CLTI...
Enrolment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialisation system (LimFlow SA) designed to prevent amputations in...
LimFlow System a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous Deep Vein Arterialisation (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...
One-year outcomes from PROMISE I US study of LimFlow system published
LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
One-year outcomes from PROMISE I US study of LimFlow system published
LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow SA announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification for the Japanese cohort of...
PROMISE I: LimFlow system enables vast majority of patients to avoid...
LimFlow SA has announced the presentation of one-year data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
Deep vein arterialisation should be considered in “no option” CLTI patients,...
Midterm results from a study of the largest population of patients with no-option chronic limb-threatening ischaemia (CLTI) treated with percutaneous deep vein arterialisation (pDVA)...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were...
First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...
LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...
PROMISE I trial affirms potential of LimFlow system for treatment of...
Initial findings of an early feasibility trial have demonstrated that the LimFlow System does represent a safe and reproducible method of treating patients with...
VIVA 2019: PROMISE I trial shows deep vein arterialisation offers hope...
Daniel Clair (Columbia, SC, USA), presented positive six-month data from the full patient cohort of the PROMISE I early feasibility study of the LimFlow...
VIVA 2019: LimFlow announces positive six-month data From PROMISE I US...
LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the...
LimFlow raises €27 million in Series C financing
LimFlow, a developer of peripheral endovascular technology focused on the treatment of critical limb ischemia (CLI), has announced it has secured €27 million (US$33.5...
LimFlow completes enrolment in US feasibility study
LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....
Positive results from pilot study of LimFlow Percutaneous Deep Vein Arterialization...
LimFlow announced on 1 August 2017 publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in...
First patient treated in LimFlow US feasibility study as international post-market...
LimFlow SA has announced enrolment of the first patient in the US feasibility study of the LimFlow percutaneous deep vein arterialisation (pDVA) system, a novel,...
LimFlow expands senior management team and opens Silicon Valley office
LimFlow, developer of minimally-invasive technology for the treatment of end-stage critical limb ischaemia (CLI), has announced the expansion of the company’s senior management team....
US FDA grants IDE approval to LimFlow for Percutaneous Deep Vein...
The US Food and Drug Administration (FDA) has approved LimFlow’s Investigational Device Exemption for a feasibility study of the company’s Percutaneous Deep Vein Arterialisation...
LimFlow receives CE mark for percutaneous critical limb perfusion system
LimFlow has received CE mark for its fully percutaneous LimFlow system designed for venous arterialisation of the lower limbs in end-stage patients at risk...
